Parasym
Parasym is a London-based neurotechnology company that develops and sells the Nuropod, a $900 non-invasive wearable auricular vagus nerve stimulator, serving consumers, elite athletes, healthcare researchers, and defense programs via DTC e-commerce and institutional partnerships.
- Company typePrivate
- Founded2014
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Parasym does
Parasym is a London-based neurotechnology company developing non-invasive auricular vagus nerve stimulation (aVNS) technology delivered through a wearable ear-electrode device. The company's proprietary approach stimulates the left tragus to modulate the parasympathetic ("rest-and-digest") nervous system, with claimed effects including increased heart rate variability (61.9% within 5 minutes), learning acquisition gains (57% in a controlled neurolinguistic study), reduction in atrial fibrillation burden (85% in paroxysmal AF patients), and modulation of anti-tumor immune responses in preclinical cancer models. The technology is supported by 60+ completed clinical studies, 100+ ongoing trials, and collaborations with research institutions including UCLA and the University of Chicago, with cumulative R&D investment stated at $10M+ over 10+ years.
The commercial product is the Nuropod, a $900 wearable device sold direct-to-consumer through the parasym.com e-commerce storefront in the U.S. market, with a separate Parasym Performance sub-brand (performance.parasym.com) targeting athletes and high-performers. The company also engages elite sports organizations, national Special Forces programs, and a network of 150+ research institutions, with researchers and healthcare professionals directed to apply for clinical and research access. Revenue mechanics center on one-time hardware sales; the institutional/access channel's pricing model is not publicly disclosed. Operations span London (HQ), Sacramento, and Tallinn, with a team of 1-10 employees.
Parasym firmographics
Firmographics- Name
- Parasym
- Legal name
- Parasym
- Website
- https://parasym.co
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Parasym is a London-based neurotechnology company that develops and sells the Nuropod, a $900 non-invasive wearable auricular vagus nerve stimulator, serving consumers, elite athletes, healthcare researchers, and defense programs via DTC e-commerce and institutional partnerships.
- Ownership category
- akta.pro rank
Parasym industry classification
Industry- Product category
- Wearable Neurostimulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)
- akta.pro secondary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
Keywords
Where Parasym is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Parasym business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Nuropod Device Sales: Parasym sells its Nuropod wearable vagus nerve stimulator as a one-time hardware purchase. The device is priced at $900 and is sold directly to consumers in the U.S. market.
- Research and Clinical Access: Parasym provides access to its research and clinical data to researchers and healthcare professionals upon application. The revenue mechanics of this channel (licensing, data access fees, or professional services) are not fully specified.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Nuropod Consumer Device |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels4 records
Parasym product offering
Product offeringCore offering
Parasym develops and sells non-invasive wearable auricular vagus nerve stimulation (aVNS) devices, with the flagship Nuropod priced at $900. The device delivers gentle electrical pulses via electrodes placed on the left tragus of the ear to modulate the parasympathetic nervous system, targeting stress reduction, recovery, HRV improvement, sleep quality, and inflammation reduction for consumers, athletes, and clinical researchers.
Product overview
Parasym offers a portfolio of non-invasive vagus nerve stimulation devices focused on neuromodulation for health and performance. The core product is the Nuropod wearable device, a $900 vagus nerve stimulator that delivers gentle electrical pulses via electrodes on the left tragus. The company also offers Parasym Performance as a sub-brand targeting athletes and high performers seeking enhanced recovery, HRV improvement, and autonomic nervous system regulation. The technology platform is grounded in over 60 clinical studies and partnerships with institutions including UCLA and the University of Chicago.
Differentiator
Problem solved
Functional benefit
Brands
- Nuropod: Wearable vagus nerve stimulator device designed to reduce stress and enhance recovery through auricular VNS stimulation.
- Parasym Performance
Products and services
- Nuropod A wearable vagus nerve stimulator designed to reduce stress by delivering gentle electrical pulses through electrodes placed on the left tragus of the ear. It stimulates the vagus nerve to enhance recovery, autonomic nervous system regulation, HRV improvement, sleep quality, and inflammation reduction.
- Parasym Performance A sub-brand offering focused on performance optimization, enabling users to command calm and perform on demand through targeted vagus nerve stimulation for athletes and high performers seeking enhanced recovery and autonomic regulation.
Quantifiable outcome
- 57% improvement in learning acquisition (long-term retention of learned second-language vocabulary at 7-day recall vs. placebo)
- +4 more outcomes
Companies that use Parasym
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Parasym technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Parasym partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- UCLAcoreParasym developed its Nuropod vagus nerve stimulation technology in partnership with UCLA, one of the world's leading research universities. UCLA's involvement provides academic credibility and research infrastructure supporting the device's clinical validation.
- University of ChicagocoreParasym developed its technology in partnership with the University of Chicago, contributing research expertise to the clinical validation of its auricular vagus nerve stimulation device.
- 150+ Elite Research InstitutionscoreParasym is trusted by 150+ internationally recognized institutions that serve as research and clinical trial partners. These partnerships span elite universities, sports organizations, and national programs. The company conducts 100+ ongoing clinical studies across all major health and performance applications through these partnerships.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Parasym competitors and assessment
Company assessmentDirect peers
- electroCore: electroCore manufactures gammaCore, a non-invasive vagus nerve stimulation (nVNS) device cleared for migraine, cluster headache, and certain autonomic indications. It is the closest direct competitor to Parasym in portable, non-invasive VNS hardware and is pursuing overlapping clinical and consumer applications.
- Neuvana: Neuvana markets a consumer non-invasive vagus nerve stimulation earbud product aimed at stress relief, relaxation, and focus. It is the closest direct peer to Parasym on the consumer/aVNS side, with a similar product form factor and stress/wellness value proposition.
- Apollo Neuroscience: Apollo Neuroscience builds a wearable device that uses gentle vibrations to influence the autonomic nervous system, targeting stress, sleep, and focus. It targets the same primary consumer segment (stress and HRV regulation) as Parasym and competes for the same DTC wellness buyer.
Broad incumbents
- LivaNova (VNS Therapy): LivaNova's VNS Therapy is the established, implanted vagus nerve stimulation system for drug-resistant epilepsy and depression. It is the broad incumbent in the VNS category and defines the surgical standard that Parasym's non-invasive platform positions against.
Emerging players
- Cefaly: Cefaly produces an external trigeminal nerve stimulation device FDA-cleared for migraine prevention and acute treatment. It is an emerging player in the consumer-prescription neurostimulation space, with overlapping non-invasive cranial stimulation use cases and customer profiles.
- Muse (Interaxon): Muse produces a consumer EEG brain-sensing headband for meditation, focus, and sleep. It is an emerging player in the consumer neurotechnology category, addressing overlapping mental wellness and nervous system regulation outcomes for a similar affluent wellness buyer.
- Dreem: Dreem builds a sleep-focused EEG headband with neurofeedback and stimulation capabilities, targeting sleep quality and stress reduction. It is an emerging player in consumer neurotechnology, with overlapping use cases in sleep, HRV, and nervous system regulation that intersect with Parasym's value proposition.
Others
- WHOOP: WHOOP is a performance wearable focused on recovery, strain, sleep, and HRV tracking, with strong penetration into professional sports and high-performance consumers. It is adjacent to Parasym, competing for the same elite-athlete and high-performer wallet but via biometric tracking rather than neurostimulation.
- Oura: Oura produces a smart ring focused on sleep, readiness, HRV, and stress insights for consumers and enterprise wellness programs. It is adjacent infrastructure for the same consumer stress/wellness category and competes for placement in employer benefit and performance programs.
- Therabody: Therabody (maker of Theragun percussive therapy devices) sells recovery and performance hardware into the same elite sports, fitness, and high-performer customer base as Parasym. It is an adjacent recovery-tech brand rather than a direct competitor, but it competes for the same performance dollar.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Parasym social profiles
Digital presenceParasym financial estimates
Financial estimateRevenue estimate
Valuation estimate
Parasym leadership team
Management profileNumber of profiles
Profiles2 records
Parasym funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Parasym M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Parasym
What does Parasym do?
Parasym develops and sells non-invasive wearable auricular vagus nerve stimulation (aVNS) devices, with the flagship Nuropod priced at $900. The device delivers gentle electrical pulses via electrodes placed on the left tragus of the ear to modulate the parasympathetic nervous system, targeting stress reduction, recovery, HRV improvement, sleep quality, and inflammation reduction for consumers, athletes, and clinical researchers.
Is Parasym a public or private company?
Parasym is a private company. It is classified as unknown and is currently operating.
When was Parasym founded?
Parasym was founded in 2014. It employs 1 to 10 people.
Where is Parasym based?
Parasym is headquartered in London, United Kingdom, in the Europe region.
How does Parasym make money?
Two revenue lines are on record. Nuropod Device Sales are the primary driver. The others are research and Clinical Access.
Who are Parasym's main competitors?
Direct peers on record are electroCore, Neuvana and Apollo Neuroscience. LivaNova (VNS Therapy) is listed as a broad incumbent. Emerging players are Cefaly, Muse (Interaxon) and Dreem. Others are WHOOP, Oura and Therabody.
Does Parasym have an API?
No public API is recorded for Parasym.
What industry is Parasym in?
Parasym's product category is Wearable Neurostimulation Devices. Its primary akta.pro industry code is CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices), with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.